Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mifen Chen"'
Autor:
Hui Chen, Lin Shen, Qi Zhang, Jian Li, Xiaochen Zhao, Jifang Gong, Zhenghang Wang, Xicheng Wang, Zhongwu Li, Yuezong Bai, Shiqing Chen, Changsong Qi, Feilong Zhao, Mifen Chen, Zhi Peng, Xiaotian Zhang, Jinping Cai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/80f04827a78b49bb86c8bfbbf9a1b972
Publikováno v:
Trends in Plant Science. 28:630-645
Publikováno v:
Expert Opinion on Biological Therapy. 22:1227-1232
Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors mobilize and activate the anti-tumor activity of the immune system by blocking the inhibitory effects of the PD-1/PD-L1 signaling pathway in T cells. Several anti-PD-1 or -PD-L1 mon
Autor:
Chunhua Wu, Wenfei Li, Mifen Chen, Qi Zhang, Ting Xu, Yao Ma, Wanyi Liu, Zhenghang Wang, Xicheng Wang, Jian Li, Tanios Bekaii-Saab, Lin Shen
Publikováno v:
Holistic Integrative Oncology. 2
KRAS is the most frequently mutated oncogene in human malignancies, observed in approximately two in five colorectal cancers (CRC). KRAS mutations were historically considered “undruggable” ten years ago and associated with resistance to EGFR tar
Autor:
Mifen Chen, Zhenghang Wang, Zimin Liu, Ting Deng, Xiaodong Wang, Zhiwei Chang, Qi Zhang, Wenlei Yang, Ning Liu, Zhi Ji, Xiaotian Zhang, Xicheng Wang, Zhi Peng, Yi Li, Yujuan Cao, Xuan Jin, Hongxia Lu, Huajun Qu, Yong Tang, Chunlei Xu, Weijia Fang, Hangyu Zhang, Dong Yan, Li Wang, Jiayi Li, Jingdong Zhang, Qiwei Wang, Liying Xue, Fei Yin, Guangjie Han, Zhiqiang Cheng, Qing Liu, Yongdong Jin, Yinjie Zhang, Lanxing Li, Baoshan Cao, Yanhong Yao, Zhiyu Chen, Jianling Zou, Jieer Ying, Qing Wei, Tiantian Tian, Weifeng Zhao, Longmei Li, Tong Zhang, Fanghua Song, Ya-er Ba, Na Li, Hui Gao, Yinghua Ji, Liying Bao, Xiaochen Zhao, Jinping Cai, Zheping Yuan, Lin Shen, Jian Li
Publikováno v:
JCO Precision Oncology.
PURPOSE To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers. METHODS We retrospectively rec
Autor:
Mifen, Chen, Zhenghang, Wang, Zimin, Liu, Ning, Liu, Weijia, Fang, Hangyu, Zhang, Xuan, Jin, Jiayi, Li, Weifeng, Zhao, Huajun, Qu, Fanghua, Song, Zhiwei, Chang, Yi, Li, Yong, Tang, Chunlei, Xu, Xiaotian, Zhang, Xicheng, Wang, Zhi, Peng, Jinping, Cai, Jian, Li, Lin, Shen
Publikováno v:
Cancers; Volume 14; Issue 20; Pages: 5158
Background: In microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers, the optimum therapy after the progression of immune checkpoint inhibitors (ICIs) is yet unknown. Here, we compared the efficacy of programmed d
Autor:
Qi Zhang, Mifen Chen, Zhenghang Wang, Changsong Qi, Yanshuo Cao, Junyan Zhang, Zhi Peng, Xicheng Wang, Ming Lu, Lin Shen, Jian Li
Publikováno v:
Clinical colorectal cancer. 21(3)
Regorafenib and fruquintinib are tyrosine kinase inhibitors that are recommended for refractory colorectal cancer (CRC) in China. However, to date, no head-to-head trials have been conducted to guide clinical practice.An ambispective observational co
Publikováno v:
Journal of experimental botany. 73(1)
Plants dynamically synchronize their flowering time with changes in the internal and external environments through a variety of signaling pathways to maximize fitness. In the last two decades, the major pathways associated with flowering, including t
Autor:
Mifen Chen, Qi Zhang, Hui Chen, Zhenghang Wang, Ting Xu, Changsong QI, Shiqing Chen, Xiaochen Zhao, Yuezong Bai, Zhi Peng, Xicheng Wang, Xiaotian Zhang, Jifang Gong, Lin Shen, Jian Li
Publikováno v:
Journal of Clinical Oncology. 40:e15504-e15504
e15504 Background: Microsatellite stable (MSS) metastatic colorectal cancer (CRC) lacks effective treatments and has a poor prognosis. The aim of this study was to identify patients who could benefit from immunotherapy combined with anti-angiogenic t
Autor:
Zhenghang Wang, Qi Zhang, Changsong Qi, Yuezong Bai, Feilong Zhao, Hui Chen, Zhongwu Li, Xicheng Wang, Mifen Chen, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Lin Shen, Jian Li
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004703
BackgroundGastrointestinal (GI) cancer is the second most common cancer type with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype that is expected to respond to immune-checkpoint inhibitors (ICIs). However, approxim